IL-1 binding proteins

Patent metadata

Field	Value
Publication number	US-9447184-B2
Application number	US-201314141317-A
Country	US
Kind code	B2
Filing date	Dec 26, 2013
Priority date	May 14, 2010
Publication date	Sep 20, 2016
Grant date	Sep 20, 2016

Abstract

Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.

First claim

What is claimed is:

1. A method for treating a subject for a disorder in which IL-1 activity is detrimental comprising administering to the subject a binding protein, wherein the binding protein comprises first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein:
VD1 is a first heavy chain variable domain;
VD2 is a second heavy chain variable domain;
C is a heavy chain constant domain;
X1 is a linker with the proviso that it is not CH1;
X2 is an Fc region; and
n is independently 0 or 1; and

wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n, wherein:
VD1 is a first light chain variable domain;
VD2 is a second light chain variable domain;
C is a light chain constant domain;
X1 is a linker with the proviso that it is not CH1;
X2 does not comprise an Fc region; and
n is independently 0 or 1;

wherein, in said first polypeptide chain, VD1 comprises an amino acid sequence of SEQ ID NO: 204; and VD2 comprises an amino acid of SEQ ID NO: 213;
wherein, in said second polypeptide chain, VD1 comprises an amino acid sequence of SEQ ID NO: 238; and VD2 comprises an amino acid sequence of SEQ ID NO: 216; and
wherein the binding protein binds human IL-1β and human IL-1α, such that treatment for the disorder is achieved.

2. The method according to claim 1 , wherein said administering to the subject is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intra-articular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

3. A method of treating a patient suffering from a disorder in which IL-1 is detrimental comprising the step of administering a binding protein before, concurrently with, or after the administration of a second agent, wherein the binding protein comprises first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein:
VD1 is a first heavy chain variable domain;
VD2 is a second heavy chain variable domain;
C is a heavy chain constant domain;
X1 is a linker with the proviso that it is not CH1;
X2 is an Fc region; and
n is independently 0 or 1; and

wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n, wherein:
VD1 is a first light chain variable domain;
VD2 is a second light chain variable domain;
C is a light chain constant domain;
X1 is a linker with the proviso that it is not CH1;
X2 does not comprise an Fc region; and
n is independently 0 or 1;

wherein, in said first polypeptide chain, VD1 comprises an amino acid sequence of SEQ ID NO: 204; and VD2 comprises an amino acid sequence of SEQ ID NO: 213;
wherein, in said second polypeptide chain, VD1 comprises an amino acid sequence of SEQ ID NO: 238; and VD2 comprises an amino acid sequence of SEQ ID NO: 216; and
wherein the binding protein binds human IL-1β and human IL-1α;
wherein the second agent is selected from the group consisting of: an antibody, or fragment thereof, capable of binding human IL-1β; an antibody, or fragment thereof, capable of binding human IL-1α; methotrexate; a corticosteroid; a beta-agonist; an antagonist of a leukotriene; an antagonist of a leukotriene receptor; ADVAIR; an IgE inhibitor; an anti-IgE antibody; XOLAIR; a phosphodiesterase inhibitor; a PDE4 inhibitor; a xanthine; an anticholinergic drug; a mast cell-stabilizing agent; Cromolyn; an IL-4 inhibitor; an IL-5 inhibitor; an eotaxin/CCR3 inhibitor; an antagonist of histamine; an antagonist of a histamine receptor, an antagonist of prostaglandin D; an inhibitor of receptor DP1; an inhibitor of CRTH2; a TNF antagonist; a soluble fragment of a TNF receptor; ENBREL; a TNF enzyme antagonist; a TNF converting enzyme (TACE) inhibitor; a muscarinic receptor antagonist; a TGF-beta antagonist; interferon gamma; perfenidone; a chemotherapeutic agent, leflunomide; sirolimus (rapamycin) or an analog thereof, CCI-779; a COX2 or cPLA2 inhibitor; a non-steroidal anti-inflammatory drug (NSAID); an immunomodulator; a p38 inhibitor; a TPL-2 inhibitor; an MK-2 inhibitor; an NFκB inhibitor; budenoside; epidermal growth factor; cyclosporine; sulfasalazine; an amino salicylate; 6-mercaptopurine; azathioprine; metronidazole; a lipoxygenase inhibitor; mesalamine; olsalazine; balsalazide; an antioxidant; a thromboxane inhibitor; an IL-1 receptor antagonist; a growth factor; an elastase inhibitor; a pyridinyl-imidazole compound; an antibody or agonists of TNF, LT, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, EMAP-II, GM-CSF, FGF, or PDGF; an antibody to CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD90; FK506; mycophenolate mofetil; ibuprofen; prednisolone; an adensosine agonist; an antithrombotic agent; a complement inhibitor; an adrenergic agent; a kinase inhibitor; an IL-1β converting enzyme inhibitors; a T-cell signaling inhibitor; a metalloproteinase inhibitor; an angiotensin converting enzyme inhibitor; soluble cytokine receptor; soluble p55 TNF receptor; soluble p75 TNF receptor; soluble IL-1RI; soluble IL-1RII; soluble IL-6R; an anti-inflammatory cytokine; IL-4; IL-10; IL-11; and TGF-β.

4. A method for treating a subject for a disorder in which IL-1 activity is detrimental comprising administering to the subject a binding protein, wherein the binding protein comprises first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein:
VD1 is a first heavy chain variable domain;
VD2 is a second heavy chain variable domain;
C is a heavy chain constant domain;
X1 is a linker with the proviso that it is not CH1;
X2 is an Fc region; and
n is independently 0 or 1; and

wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n, wherein:
VD1 is a first light chain variable domain;
VD2 is a second light chain variable domain;
C is a light chain constant domain;
X1 is a linker with the proviso that it is not CH1;
X2 does not comprise an Fc region; and
n is independently 0 or 1;

wherein said first polypeptide chain comprises an amino acid sequence of SEQ ID NO: 212; wherein said second polypeptide chain comprises an amino acid sequence of SEQ ID NO: 215; and
wherein the binding protein binds human IL-1β and human IL-1α, such that treatment of the disorder is achieved.

5. The method according to claim 4 , wherein said administering to the subject is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intra-articular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

6. A method of treating a patient suffering from a disorder in which IL-1 is detrimental comprising the step of administering a

Assignees

• Abbvie Inc
• Abbvie Inc

Inventors

• Wu Chengbin
• Ambrosi Dominic J
• Hsieh Chung-Ming
• Ghayur Tariq

Classifications

• A61P5/14

  of the thyroid hormones, e.g. T3, T4 · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P5/50

  for increasing or potentiating the activity of insulin · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P37/02

  Immunomodulators · CPC title